ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3016% above fair value
$10.22+0.03 (+0.29%)
Close on Nov 12, 2026Market cap $92.82MP/E 51.1Yield –
ImmuCell EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
ImmuCell's EPS for the twelve months ending Sep 30, 2026 was $0.20, down 23.1% year over year. For fiscal 2025 it was -$0.12. The highest annual figure on record is $0.38 in fiscal 2015.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.12 | – |
| FY2024 | Dec 31, 2024 | -$0.26 | – |
| FY2023 | Dec 31, 2023 | -$0.75 | – |
| FY2022 | Dec 31, 2022 | -$0.32 | – |
| FY2021 | Dec 31, 2021 | -$0.01 | – |
| FY2020 | Dec 31, 2020 | -$0.14 | – |
| FY2019 | Dec 31, 2019 | -$0.19 | – |
| FY2018 | Dec 31, 2018 | -$0.42 | – |
| FY2017 | Dec 31, 2017 | -$0.03 | -125.0% |
| FY2016 | Dec 31, 2016 | $0.12 | -68.4% |
| FY2015 | Dec 31, 2015 | $0.38 | – |
| FY2014 | Dec 31, 2014 | -$0.06 | -250.0% |
| FY2013 | Dec 31, 2013 | $0.04 | +33.3% |
| FY2012 | Dec 31, 2012 | $0.03 | – |
| FY2011 | Dec 31, 2011 | -$0.14 | – |
| FY2010 | Dec 31, 2010 | -$0.13 | – |
| FY2009 | Dec 31, 2009 | -$0.07 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.10 | – |
| Q2 FY2026 | Jun 30, 2026 | $0.20 | +233.3% |
| Q1 FY2026 | Mar 31, 2026 | $0.21 | +31.3% |
| Q4 FY2025 | Dec 31, 2025 | -$0.31 | -616.7% |
| Q3 FY2025 | Sep 30, 2025 | -$0.02 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.06 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.16 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.06 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.09 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.20 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.06 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.15 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.12 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.18 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.30 | -528.6% |
| Q4 FY2022 | Dec 31, 2022 | -$0.22 | -2300.0% |
| Q3 FY2022 | Sep 30, 2022 | -$0.08 | -500.0% |
| Q2 FY2022 | Jun 30, 2022 | -$0.09 | -550.0% |
| Q1 FY2022 | Mar 31, 2022 | $0.07 | – |
| Q4 FY2021 | Dec 31, 2021 | $0.01 | -66.7% |
| Q3 FY2021 | Sep 30, 2021 | $0.02 | – |
| Q2 FY2021 | Jun 30, 2021 | $0.02 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.06 | – |
| Q4 FY2020 | Dec 31, 2020 | $0.03 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.04 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.11 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.02 | -166.7% |
| Q4 FY2019 | Dec 31, 2019 | -$0.04 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.07 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.09 | – |
| Q1 FY2019 | Mar 31, 2019 | $0.03 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.19 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.05 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.15 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.04 | -133.3% |
| Q4 FY2017 | Dec 31, 2017 | -$0.04 | -500.0% |
| Q3 FY2017 | Sep 30, 2017 | -$0.07 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.05 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.12 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.01 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?